Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWei SuUniversity of Hawaiʻi at MānoaJHJianhua HanChinese Academy of Medical Sciences & Peking Union Medical College

Discussion

Loading...

Member takes

Overview

Mass spectrometry screening improved detection of monoclonal gammopathy in 15,068 individuals, suggesting it aids clinical monitoring and risk stratification.

Key Points

  • This research evaluates the feasibility of mass spectrometry for screening monoclonal gammopathy in individuals undergoing physical examinations.
  • Prospective enrollment of 15,068 individuals aged ≥30 years from Peking Union Medical College Hospital.
  • Utilized iMS-LC Assay for automated screening of residual serum samples from traditional serum protein electrophoresis tests.
  • Positive samples confirmed using serum immunofixation electrophoresis, free light chain analysis, and MS isotyping.
  • Mass spectrometry identified 201 positive cases, outperforming serum protein electrophoresis which found only 71 cases.
  • Confirmed 181 samples (1.19%) as true monoclonal gammopathy.
  • MS detection rates were significantly higher across all age groups, indicating earlier M-protein detection.

Cite This Study

Su et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e033https://doi.org/10.1182/blood-2025-5744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Persistence of M-proteins detected by mass spectrometry2026
  2. 2AI-augmented MALDI-TOF MS screening reveals a high burden of undiagnosed monoclonal gammopathy in adult patients2026
  3. 3Performance and additional benefits of MALDI-TOF-MS in M-protein detection in plasma cell disorders2026
  4. 4Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL2025
  5. 5Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial2025